Myeloperoxidase (MPO) and high sensitivity C-reactive protein (hsCRP) as inflammatory biomarkers of endothelial and leukocyte activation in overweight hypertensive patients
Abstract
Background: Low-grade inflammation mediates the relation between overweight and the development of cardiovascular diseases. The study aimed to examine if myeloperoxidase (MPO) and hsCRP (high-sensitivity C-reactive protein) in overweight hypertensive patients can be used as biomarkers of endothelial and leukocyte activation.
Material and methods: Seventy-five subjects were included in the study; 38 had essential arterial hypertension (AH) and 37 were normotensive controls (NC), subsequently divided into overweight (OW; BMI ≥ 25 kg/m2) and normal weight subgroups (NW; BMI < 25 kg/m2). Body mass index (BMI), inflammatory markers concentrations, association of MPO and hsCRP with AH and/or overweight were assessed.
Results: AH patients had higher MPO (median 132.5 pmol/L, IQR: 53.8–691.9) (p < 0.001), while hsCRP did not significantly differ compared to normotensive controls (NC). NW-AH patients had higher MPO (p = 0.02) than normotensive NW patients. MPO was similar between normotensive patients OW and NW, while hsCRP concentration was significantly higher in the OW (median 1.85 mg/L, IQR: 0.47–7.19) (p = 0.01) compared to NW. OW-AH patients had significantly higher MPO (median 137.4 pmol/L, IQR: 53.80–703.4) (p = 0.002) compared to normotensive NW and OW (p < 0.001) patients, likely reflecting neutrophilic activation in hypertension. Additionaly, OW-AH patients had significantly higher hsCRP (median 1.71 mg/L, IQR: 0.22–14) (p = 0.005) than normotensive NW patients. hsCRP significantly positively correlated with BMI in both AH (r = 0.41, p = 0.009) and NC groups (r = 0.38, p = 0.01), while MPO did not correlate, supporting inflammation in OW, particularly in OW with AH.
Conclusions: All together, the results suggest that inflammation may mediate mutual association of AH and OW, suggesting MPO as inflammatory biomarker for AH and hsCRP for overweight.
Keywords: arterial hypertensionoverweightmyeloperoxidasehigh sensitivity C-reactive proteininflammationbiomarker
References
- Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360(9349): 1903–1913.
- Jelaković B, Željković-Vrkić T, Pećin I, et al. Arterijska hipertenzija u Hrvatskoj.Rezultati EH-UH studije. Acta Med Croatica. 2007; 61: 287–92.
- Boos CJ, Lip GYH. Is hypertension an inflammatory process? Curr Pharm Des. 2006; 12(13): 1623–1635.
- Kakar P, Lip GYH. Towards understanding the aetiology and pathophysiology of human hypertension: where are we now? J Hum Hypertens. 2006; 20(11): 833–836.
- Sinisalo J, Paronen J, Mattila KJ, et al. Relation of inflammation to vascular function in patients with coronary heart disease. Atherosclerosis. 2000; 149(2): 403–411.
- Schwedler SB, Kuhlencordt PJ, Ponnuswamy PP, et al. Native C-reactive protein induces endothelial dysfunction in ApoE-/- mice: implications for iNOS and reactive oxygen species. Atherosclerosis. 2007; 195(2): e76–e84.
- Libby P. Inflammation in atherosclerosis. Nature. 2002; 420(6917): 868–874.
- Steffel J, Lüscher TF. Predicting the development of atherosclerosis. Circulation. 2009; 119(7): 919–921.
- Kim JS, Kang TS, Kim JB, et al. Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis. 2007; 192(2): 401–406.
- Souza JR, Oliveira RT, Blotta MH, et al. Serum levels of interleukin-6 (Il-6), interleukin-18 (Il-18) and C-reactive protein (CRP) in patients with type-2 diabetes and acute coronary syndrome without ST-segment elevation. Arq Bras Cardiol. 2008; 90(2): 86–90.
- Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002; 106(12): 1439–1441.
- Hein TW, Singh U, Vasquez-Vivar J, et al. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 2009; 206(1): 61–68.
- Guan H, Wang P, Hui R, et al. Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem. 2009; 55(2): 274–284.
- Calabro P, Chang DW, Willerson JT, et al. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol. 2005; 46(6): 1112–1113.
- Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996; 312(7038): 1061–1065.
- Norman PE, Powell JT. Vitamin D, shedding light on the development of disease in peripheral arteries. Arterioscler Thromb Vasc Biol. 2005; 25(1): 39–46.
- Klinke A, Nussbaum C, Kubala L, et al. Myeloperoxidase attracts neutrophils by physical forces. Blood. 2011; 117(4): 1350–1358.
- Schindhelm RK, van der Zwan LP, Teerlink T, et al. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem. 2009; 55(8): 1462–1470.
- Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000; 275(48): 37524–37532.
- Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002; 296(5577): 2391–2394.
- Sung KC. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003; 16(6): 429–433.
- Bautista LE, López-Jaramillo P, Vera LM, et al. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001; 19(5): 857–861.
- Shafi Dar M, Pandith AA, Sameer AS, et al. hs-CRP: A potential marker for hypertension in Kashmiri population. Indian J Clin Biochem. 2010; 25(2): 208–212.
- Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005; 19(2): 149–154.
- Van der Zwan LP, Scheffer PG, Dekker JM, et al. Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. Hypertension. 2010; 55(6): 1366–1372.
- Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999; 19(4): 972–978.
- Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. 2000; 102(9): 994–999.
- Bautista LE, Atwood JE, O'Malley PG, et al. Association between C-reactive protein and hypertension in healthy middle-aged men and women. Coron Artery Dis. 2004; 15(6): 331–336.
- Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003; 290(22): 2945–2951.
- Fabijanić D, Banić M, Kardum D. C-reaktivni protein u procjeni kardiovaskularnog rizika. Liječ Vjesn. 2006; 128: 167–74.
- Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999; 19(8): 1986–1991.
- Mitu F, Rezuş E, Banu C, et al. Inflammatory markers in hypertensive patients and influence of some associated metabolic risk factor. Rev Med Chir Soc Med Nat Iasi. 2014; 118(3): 631–636.
- Lakoski SG, Cushman M, Siscovick DS, et al. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2005; 46(10): 1869–1874.
- Pankow J, Folsom A, Cushman M, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis. 2001; 154(3): 681–689.
- Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res. 2004; 12(2): 180–186.
- Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001; 103(13): 1813–1818.